Soquelitinib Clinical Trials (2026): 4 Studies for Atopic Dermatitis & Atopic Dermatitis Eczema
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
4 Soquelitinib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 3 indications (including Atopic Dermatitis & Atopic Dermatitis Eczema) and 447 total planned enrollment. 1 Phase 3 Soquelitinib trial and 2 Phase 2 are listed. 3 Soquelitinib clinical trials are actively recruiting at 25 U.S. sites across 18 states. Most recent activity: NCT06561048 (Dec 2028).
Where to Participate: All Soquelitinib Trial Sites in the U.S. (25 sites across 18 states)
Every actively recruiting Soquelitinibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | City of Hope National Medical Center | Duarte91010 | NCT06561048 | Map |
| CA | University of California, Irvine | Irvine92697 | NCT06561048 | Map |
| CA | University of California San Francisco | San Francisco94143 | NCT06561048 | Map |
| CA | Corvus Clinical Trials | South San Francisco94080 | NCT07441395 | Map |
| CT | Yale University | New Haven06520 | NCT06561048 | Map |
| FL | Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine | Miami33136 | NCT06561048 | Map |
| GA | Emory University | Atlanta30322 | NCT06561048 | Map |
| IL | North Western University Robert H. Lurie Comprehensive Cancer Center RHLCCC | Chicago60611 | NCT06561048 | Map |
| IA | University of Iowa | Iowa City52242 | NCT06561048 | Map |
| MD | University of Maryland Medical Center | Baltimore21201 | NCT06561048 | Map |
| MD | National Institutes of Health Clinical Center | Bethesda20892 | NCT06730126 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT06561048 | Map |
| MI | Roger Cancer Center University of Michigan Health | Ann Arbor48109 | NCT06561048 | Map |
| MO | Washington University in St. Louis | St Louis63130 | NCT06561048 | Map |
| NJ | Hackensack University Medical Center | Hackensack07601 | NCT06561048 | Map |
| NY | Icahn School of Medicine at Mount Sinai | New York10029 | NCT06561048 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT06561048 | Map |
| NY | Weill Cornell Medicine | New York10065 | NCT06561048 | Map |
| NC | North Carolina Cancer Hospital | Chapel Hill27514 | NCT06561048 | Map |
| OH | The Ohio State University | Columbus43210 | NCT06561048 | Map |
| PA | The Children's Hospital of Philadelphia | Philadelphia19104 | NCT06730126 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT06561048 | Map |
| TX | Texas Children's Hospital | Houston77030 | NCT06730126 | Map |
| WA | University of Washington Fred Hutch Cancer Center | Seattle98109 | NCT06561048 | Map |
| WI | University of Wisconsin Carbone Cancer Center | Madison53792 | NCT06561048 | Map |
Soquelitinib clinical trials at a glance: phase × recruitment status
| Phase | recruiting | completed | Total |
|---|---|---|---|
| P1 | 1 | 1 | |
| P2 | 2 | 2 | |
| P3 | 1 | 1 |
Recruiting Soquelitinib clinical trials (3)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06561048 | Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma | P3 | Peripheral T-Cell Lymphoma, Not Otherwise Specified | 150 | Oct 2024 |
| NCT07441395 | SIERRA1Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD | P2 | Atopic Dermatitis | 200 | Feb 2026 |
| NCT06730126 | ALPSStudy of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients | P2 | Autoimmune Lymphoproliferative Syndrome | 15 | Mar 2025 |
Soquelitinib clinical trials by indication
Atopic Dermatitis (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07441395 | SIERRA1 | P2 | recruiting | Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD |
| NCT06345404 | — | P1 | completed | Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD |
Autoimmune Lymphoproliferative Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06730126 | ALPS | P2 | recruiting | Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients |
Peripheral T-Cell Lymphoma, Not Otherwise Specified (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06561048 | — | P3 | recruiting | Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma |
Soquelitinib pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| SIERRA1 | NCT07441395 | P2 | recruiting | Atopic Dermatitis | 200 | — |
| ALPS | NCT06730126 | P2 | recruiting | Autoimmune Lymphoproliferative Syndrome | 15 | PMID 24398331 |
All Soquelitinib trials (4)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06561048 | Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma | P3 | recruiting | 150 | Corvus Pharmaceuticals, Inc. | Oct 2024 | |
| NCT07441395 | SIERRA1 | Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD | P2 | recruiting | 200 | Corvus Pharmaceuticals, Inc. | Feb 2026 |
| NCT06730126 | ALPS | Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients | P2 | recruiting | 15 | National Institute of Allergy and Infectious Diseases (NIAID) | Mar 2025 |
| NCT06345404 | Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD | P1 | completed | 82 | Corvus Pharmaceuticals, Inc. | Apr 2024 |
Soquelitinib clinical trials: frequently asked questions
- How many Soquelitinib clinical trials are there?
- 4 Soquelitinib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 3 are actively recruiting participants. 1 is marked completed.
- Are Soquelitinib clinical trials recruiting in 2026?
- Yes — 3 Soquelitinib trials are actively recruiting in 2026, with 25 U.S. sites across 18 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Soquelitinib being studied for?
- Soquelitinib is being studied for Atopic Dermatitis, Atopic Dermatitis Eczema, Autoimmune Lymphoproliferative Syndrome, Eczema, Eczema, Atopic and 7 more. The trials are grouped by indication on this page.
- What phase is Soquelitinib in?
- Soquelitinib clinical trials span 1 Phase 3, 2 Phase 2, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Soquelitinib clinical trials?
- The lead sponsor across the most Soquelitinib trials is Corvus Pharmaceuticals, Inc., with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Soquelitinibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: